Blood Test Detects 50 Types of Cancer Before Symptoms: The British Revolution
One tube of blood. Ten milliliters. Twenty minutes to collect. On March 29, 2026, researchers from Cancer Research UK and University College London published in The Lancet Oncology the results of the largest prospective study ever conducted on multi-cancer detection through blood tests.
The PATHFINDER-UK study followed 142,600 volunteers over 3 years (2023-2026). All participants — healthy and without prior diagnosis — underwent a test that analyzes fragments of circulating tumor DNA (ctDNA), microscopic pieces of genetic material that tumors release into the bloodstream months before any symptoms appear.
Result: the test identified cancer in 92.3% of confirmed cases and predicted the organ of origin in 88.7%. It detected tumors of 50 different types, including pancreas, ovary, liver, and esophagus — notoriously silent cancers that are typically only discovered at advanced stages.
How It Works: The Science of Liquid Biopsy
Circulating tumor DNA: the enemy's footprints
Every cell in the body contains 6.4 billion base pairs of DNA. When cells die — 60 billion per day — DNA fragments are released into the blood. Cancer cells carry characteristic mutations and methylation patterns that distinguish them from normal DNA.
The test detects these mutant fragments in an ocean of healthy DNA — a task comparable to finding 1 marked card in a deck of 10,000 cards mixed in a bucket of water.
Methylation technology
The breakthrough isn't in detecting mutations (2016 technology), but in reading methylation patterns of ctDNA. Methylation works as a "zip code": each cancer methylates specific genome regions, creating a signature that identifies whether cancer exists, what type, and how much.
Sequencing uses NGS (Next-Generation Sequencing) that reads millions of fragments simultaneously. An OncoMeth-AI v3 algorithm, trained with 250,000 tumor samples, analyzes the patterns and delivers results within 7-14 days.
The Numbers That Change Everything
| Metric | Result |
|---|---|
| Participants | 142,600 |
| Cancers detected | 1,284 |
| True positives | 1,185 |
| Overall sensitivity | 92.3% |
| Organ prediction | 88.7% |
| False positives | 0.5% |
| Stage I-II (early) | 67.4% |
| Estimated mortality reduction | 26-31% |
Comparison with traditional screening
| Cancer type | Conventional early detection | Liquid biopsy early detection | 5-year survival detected early |
|---|---|---|---|
| Lung | 16% | 71% | 56% vs 5% |
| Pancreas | 10% | 63% | 44% vs 3% |
| Ovarian | 15% | 69% | 92% vs 17% |
| Liver | 20% | 74% | 31% vs 2% |
| Breast | 62% | 94% | 99% vs 27% |
| Colon | 39% | 88% | 91% vs 14% |
Pancreatic cancer shows the most brutal difference: 90% of cases are diagnosed at stage III-IV with 3% survival. Liquid biopsy detected 63% at stage I-II, when survival rises to 44%.
The 50 Detectable Cancer Types
The test covers virtually all solid cancers and several hematological ones:
Solid (42): lung, breast, colon, rectum, pancreas, ovary, liver, esophagus, stomach, kidney, bladder, prostate, endometrium, cervix, thyroid, head and neck, melanoma, sarcoma, osteosarcoma, glioblastoma, meningioma, mesothelioma, gallbladder, small intestine, adrenal gland, thymus, among others.
Hematological (8): chronic lymphocytic leukemia, acute myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes, acute lymphoblastic leukemia, and chronic myeloid leukemia.
History: A Decade of Development
The journey began in 2016, when GRAIL launched the concept of multi-cancer liquid biopsy. The first commercial test, Galleri, was FDA-approved in 2023.
What distinguishes PATHFINDER-UK is the scale and prospective design: 142,600 people tested before any suspicion, followed for 3 years — the "gold standard" of evidence-based medicine.
The algorithm was trained with 250,000 tumor samples, 180,000 healthy controls, and 15 million ctDNA fragments using A100 GPU clusters for 3,200 hours.
The evolution of cancer diagnostics
| Decade | Method | Main limitation |
|---|---|---|
| 1920s | Pap smear (cervical) | Only 1 cancer type |
| 1960s | Mammography | Breast only, high false positives |
| 1970s | CT scan | Ionizing radiation, high cost |
| 1990s | PSA (prostate) | Extreme overdiagnosis |
| 2000s | PET-CT | Prohibitive screening cost |
| 2010s | Genetic sequencing | Limited to known mutations |
| 2020s | Multi-cancer liquid biopsy | Still expensive |
Each generation solved one problem and created others. Liquid biopsy is the first technology with potential to unify all screenings into a single blood draw.
The technology pipeline: from tube to answer
The journey of a blood sample through the PATHFINDER-UK protocol involves sophisticated steps:
Step 1 — Collection and preparation (30 minutes): Extraction of 10 ml of venous blood followed by centrifugation to separate plasma from cells. The plasma contains fragmented ctDNA, typically ranging from 100 to 200 base pairs — much shorter than intact healthy cell DNA.
Step 2 — Free DNA extraction (2 hours): Using automated extraction kits, circulating cell-free DNA (cfDNA) is isolated from plasma. In a healthy person, there are approximately 10-15 nanograms of cfDNA per milliliter of plasma. In active cancer patients, this can rise to 50-500 ng/ml.
Step 3 — Methylation enrichment (6 hours): The most critical step. The cfDNA is treated with sodium bisulfite, converting unmethylated cytosines to uracil while preserving methylated cytosines — transforming invisible epigenetic differences into direct sequence differences the sequencer can read.
Step 4 — NGS sequencing (24-48 hours): Using Illumina NovaSeq 6000 platforms, DNA fragments are read at 30x depth. A single test generates approximately 15 gigabases of data.
Step 5 — Computational analysis (2-4 hours): The OncoMeth-AI v3 algorithm processes data, comparing observed methylation patterns against its database. The result is a risk score from 0 to 1,000 — above 350 warrants investigation.
Global regulatory landscape
Multi-cancer screening test approvals follow different paths in each jurisdiction:
- USA (FDA): PMA required — most rigorous process. Expected: 2027-2028
- Europe (CE): Under IVDR regulation, highest risk class (Class D). Expected: 2028-2029
- Japan (PMDA): Adaptive approval system in evaluation. Expected: 2027
- China (NMPA): BGI Genomics developing Chinese version with 80,000 participants. Expected: 2026-2027
Cost and Global Access
Current pricing
- USA: $949 per test (no coverage in most plans)
- UK: £295 per test in the study; NHS evaluating universal coverage for 50+
- Brazil: Not yet available; projection R$2,000-3,500 in private labs (2028-2029)
Cost-effectiveness analysis (BMJ)
For universal British coverage above 50:
- Annual cost: £3.4 billion
- Savings in avoided treatments: £5.1 billion
- Net savings: £1.7 billion/year
- Lives saved: 22,000-28,000 in the UK annually
Global projection
| Country | Candidates 50+ | Estimated cost | Lives saved/year |
|---|---|---|---|
| United Kingdom | 22 million | £3.4B | 22,000-28,000 |
| USA | 113 million | $26B | 115,000-142,000 |
| Brazil | 54 million | R$52B | 48,000-62,000 |
| Global | 1.2 billion | — | 1.5-2.0 million |
Implemented globally, the test could save up to 2 million lives per year.
Limitations and Controversies
False positives at scale
A 0.5% rate sounds low, but across 22 million Britons means 110,000 people with incorrect positive results — generating anxiety, additional invasive tests, and healthcare system costs.
Overdiagnosis
Indolent tumors (that would never cause symptoms) may be treated unnecessarily. The study addresses this with "active surveillance" protocols for low-risk tumors.
Access inequality
At $949 per test, the technology will initially benefit only those who can afford it, widening health inequality. Public programs will be essential for democratization.
What Experts Say
Prof. Peter Johnson, Cancer Research UK: "These results indicate we're at the threshold of a fundamental change in how we detect and treat cancer."
Dr. Luiz Henrique Gebrim, Hospital Pérola Byington (SP): "Brazil should seriously consider incorporating this technology into the SUS."
The Silent Revolution of Early Detection
Cancer kills 10 million people per year globally — the second leading cause of death on the planet. Of that total, an estimated 4.5 million die because diagnosis came too late.
The multi-cancer liquid biopsy isn't a cure. It's something potentially more powerful: a fair chance. The chance to find the enemy while it's still small, weak, and treatable.
The future of oncology is in 10 ml of blood.
Also Read
- Hair Follicle in Laboratory: End of Baldness?
- Polylaminina: Spinal Cord Regeneration
- Deadly Viral Challenges on the Internet
FAQ — Frequently Asked Questions
Does the test replace mammography, colonoscopy, and other traditional exams?
No. Liquid biopsy is complementary. The blood test has variable sensitivity by cancer type — for breast and colon, traditional exams still detect very early stages better. The great advantage is covering cancers without traditional screening (pancreas, ovary, liver, esophagus), responsible for over 70% of cancer deaths without effective screening.
Can the test give a false negative?
Yes, with 7.7% probability. Generally these are very small tumors (stage 0 or early I) that release minuscule amounts of ctDNA. Sensitivity varies: breast and colon above 94%, brain cancers around 68%. Annual testing is recommended.
What does it cost and will health insurance cover it?
USA: $949, no coverage in most plans. UK: £295 in the study, NHS evaluating universal coverage for 50+. Brazil: unavailable, projection R$2,000-3,500. DNA sequencing has dropped 99.99% in cost since 2001 (from $2.7 billion to $200 in 2026). As more data proves cost-effectiveness, insurers and public systems should eventually cover it.
Sources and References
- The Lancet Oncology — "PATHFINDER-UK: Multi-cancer early detection via cfDNA methylation — 3-year prospective results" — March 29, 2026
- Cancer Research UK — "Blood test detects 50 cancers before symptoms in largest study" — March 2026
- British Medical Journal — "Cost-effectiveness of population-level multi-cancer screening in the UK" — March 2026
- GRAIL Inc. — "Galleri test clinical evidence 2023-2026" — March 2026
- Nature Reviews Cancer — "Cell-free DNA methylation: the frontier in cancer screening" — February 2026
